【摘要】：Objective:To analyze the efficacy and side-effect of teniposide plus cisplatin regimen on malignant glioma patients.Methods:A total of 56 patients with histologically confirmed malignant gliomas(WHO grade III/IV) were analyzed.All patients were received radiotherapy following surgery.There were 24 patients received adjuvant chemotherapy and the other 32 patients received salvage chemotherapy.The chemotherapy regimen comprised of VM-26 300mg/m2 plus DDP 80 mg/m2,which were divided for 3-5 days intravenous administration,every 3-4 weeks as a cycle.The clinical efficacy and survival time of the patients were evaluated if the patients who were completed more than two cycles chemotherapy.Results:Forty-nine patients were included for evaluation:complete remission(CR) was achieved in 2 cases(4.1%)and 6 cases(12.2%) were partial remission(PR),while stable disease(SD)were found in 30 patients(61.3%),and progressive disease(PD) were in 11 cases(22.4%).Objective response rate(CR+PR) was 16.3%,and disease control rate(CR+PR+SD) was 77.6%.The progression-free survival(PFS) rate at 6 months was 55.1%.The survival rate at 1 year,2 years and 3 years was 63.3%,34.7%,and 20.4%,respectively.The median overall survival time(OS) was 20.8 months.The side-effect of the regimen was mainly hematological,with grade 3 or 4 neutropenia in twelve patients(24.5%),and which was recovered in several days after receiving G-CSF treatment.Conclusion:VM-26 plus DDP chemotherapy regimen can achieve fairly high response rate and disease control rate for patients with malignant gliomas,and the toxicity is acceptable.